HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketing in Brief: X Body Talk

This article was originally published in The Rose Sheet

Executive Summary

X Body Talk: Unisex scent to be supported by a $2 mil. ad budget for the fourth quarter, with TV spots running on cable networks such as Black Entertainment Television and MTV, and print ads appearing in Rolling Stone and Vibe, according to Intercosmetic, the U.S. division of Wella Fragrances & Cosmetics Group. The "hip and cool" mass market scent is geared toward men and women ages 15 to 25, according to the company. Supplied by Firmenich, the fragrance opens with lime, geranium, galbanum, bergamot and marine notes, leading to a "fresh" heart of rose, jasmine, lavandin, cypress, carnation and clary sage. The "warm, sensual" and woody drydown comprises patchouli, sandalwood, musk and amber. Packaged in a clear, glass bottle with a grooved silver cap, a 3.4 oz. eau de toilette will be priced at $23...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel